➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Merck
Johnson and Johnson
Moodys
Baxter

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 6,277,987

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,277,987
Title: Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives
Abstract:Compounds of formula ##STR1## wherein W is --OH or --NHOH; X is a heterocycle with the proviso that when X is a nitrogen containing heterocycle, the heterocycle is attached to the (CH.sub.2).sub.m moiety by a ring nitrogen, --CONR.sub.2 R.sub.3, --NR.sub.1 COR.sub.2, --NR.sub.1 SO.sub.2 R.sub.2, --NR.sub.1 CONR.sub.2 R.sub.3, --NR.sub.1 COOR.sub.4, heteroarylthio, alkylthio, arylalkylthio, heteroarylalkylthio, heterocycloalkylalkylthio, heterocycloalkylthio or arylthio; Y is carbon, nitrogen, oxygen or sulfur, provided that when Y is carbon, n is 2; Z is alkyl, aryl, alkoxy, aryloxy, aralkoxyaryl, aralkoxyheteroaryl, heteroaryl, heterocycloalkyl, heteroaryloxy, --CONR.sub.2 R.sub.3, --NR.sub.1 COR.sub.2, --NR.sub.1 CONR.sub.2 R.sub.3, --OCONR.sub.2 R.sub.3, --NR.sub.1 COOR.sub.4, or --SO.sub.2 R.sub.2 ; R.sub.1 is hydrogen, alkyl, heterocycloalkylalkyl, aralkyl or heteroarylalkyl; R.sub.2 and R.sub.3 are independently R.sub.1, aryl or heteroaryl; or R.sub.2 and R.sub.3 taken together with the nitrogen atom to which they are attached form a 5- to 7-membered ring, which may optionally contain another heteroatom selected from oxygen, nitrogen and sulfur; R.sub.4 is alkyl, heterocycloalkylalkyl, aralkyl, aryl or heteroaryl; m represents an integer from one to six; n represents the integer one or two; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting matrix-degrading metalloproteinases in mammals using such compounds. Compounds of formula I are inhibitors of matrix-degrading metalloproteinases and are useful for the treatment of conditions related thereto.
Inventor(s): Kukkola; Paivi Jaana (Whitehouse Station, NJ), Robinson; Leslie Anne (Del Mar, CA), Nakajima; Motowo (Ashiya, JP), Sakaki; Junichi (Takarazuka, JP)
Assignee: Novartis AG (Basel, CH)
Application Number:09/243,854
Patent Claims:see list of patent claims

Details for Patent 6,277,987

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial Novartis AG (Basel, CH) 2018-02-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Dow
Merck
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.